PEN FRAUD CLAIMS EXPAND: Hagens Berman Encourages Penumbra (PEN) Investors to Contact the Firm, Investigation Expanded to Cover More Recent Claims of Fraud
ACCESSWIRE, 31 December 2020
The investigation centers on whether Penumbra misled investors about the company’s flagship products for treating ischemic stroke.
On Nov. 9, 2020, research firm Quintessential Capital Management (“QCM”) published a scathing report about “Penumbra and its ‘killer catheter'”, concluding: (1) “Penumbra’s flagship ‘Jet 7′ device is linked to 18 recorded deaths, 39 injuries: this might be only the ‘tip of the iceberg;'” (2) “[t]he device is unsafe and unmarketable: we believe an FDA class 1 recall highly likely”; (3) “Penumbra may have been highly misleading in critical parts of its communication with doctors and investors;” and, (4) “[d]espite appearances, financial metrics are rapidly deteriorating, anticipating a possible sharp drop in sales.”
Continue reading “Article: PEN FRAUD CLAIMS EXPAND: Hagens Berman Encourages Penumbra (PEN) Investors to Contact the Firm, Investigation Expanded to Cover More Recent Claims of Fraud”
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MultiPlan (MPLN) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
Globe Newswire, 08 December 2020
The investigation centers on MultiPlan’s financial disclosures leading up to- and through- its merger and going public transaction with special purpose acquisition (“SPAC”) company Churchill Capital Corp. III. More specifically, Hagens Berman is investigating the company’s and its sponsor’s statements about MultiPlan’s client base and revenues. On Nov. 11, 2020, Muddy Waters Capital published a scathing report, “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab,” based in part on its interviews of former MultiPlan executives.
Among other things, Muddy Waters observes: (1) the company and its sponsors concealed the impending loss of MultiPlan’s largest client (“UnitedHealthcare”, or “UHC”) due to UHC’s formation of a competitor (“Naviguard”) that offers significantly lower prices and fewer conflicts of interest; (2) MultiPlan’s financials “have been financially engineered to obscure the decay in its business;” and, (3) “[w]e understand that in 2018, MPLN released revenue reserves, dropping them from approximately 30% to 10% of revenue, which we believe enabled MPLN to show 2018 EBITDA growth amid shrinking sales.”
Continue reading “Article: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MultiPlan (MPLN) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud”
Novagold says potential class action amateurish, ignorant
Cecilia Jamasmie, 10 July 2020
Canada’s Novagold (TSX, NYSE: NG), which is suing short-selling firm J Capital Research (JCAP) for defamation, said a US law firm’s potential attempt to launch a class suit against the company on alleged securities fraud would be based on “malicious and false information”. Lawyers at Hagens Berman and Portnoy said this week they were investigating whether Novagold had misled investors about the viability of its Donlin gold project, in Alaska.
Novagold said the move by San Francisco-based Hagens Berman appeared to be entirely based on JCAP’s “tapestry of deceit” as well as “false and misleading statements” about the company and its 50-50 development partner in the project, Barrick Gold (TSX: ABX) (NYSE: GOLD).
Continue reading “Article: Novagold says potential class action amateurish, ignorant”
LOOP SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages Loop Industries (LOOP) Investors to Contact Its Attorneys, Securities Fraud Action Filed, Application Deadline Approaching
GLOBE NEWSWIRE, 30 November 2020
The complaint alleges that Loop made false and misleading statements about its purportedly “proven” technology that breaks down PET plastic to its base chemicals at a recovery rate of 100%. The complaint also alleges that Loop misrepresented its partnerships with key customers.
Specifically, the complaint alleges that Defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loop’s purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loop’s announced partnerships with Indorama and Thyssenkrupp.
Continue reading “Article: LOOP SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages Loop Industries (LOOP) Investors to Contact Its Attorneys, Securities Fraud Action Filed, Application Deadline Approaching”